Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

GlobeNewswire October 22, 2014

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)

GlobeNewswire October 1, 2014

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)

Newsfile October 1, 2014

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)

GlobeNewswire October 1, 2014

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

GlobeNewswire September 16, 2014

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

GlobeNewswire September 15, 2014

RedHill Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

GlobeNewswire September 4, 2014

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis

GlobeNewswire September 3, 2014

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA

GlobeNewswire August 27, 2014

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101

GlobeNewswire August 13, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

RedHill Biopharma Reports Results for the Second Quarter of 2014

GlobeNewswire July 23, 2014

RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24, 2014

GlobeNewswire July 16, 2014

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG

GlobeNewswire June 30, 2014

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data With RHB-104 for the Treatment of Type 1 Diabetes

GlobeNewswire June 26, 2014

RedHill Biopharma to Present at the 2014 BIO International Convention

GlobeNewswire June 18, 2014

RedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference

GlobeNewswire June 11, 2014

LabStyle Innovations Corp.'s CEO To Present At RetailInvestorConferences.com On June 5th

Accesswire June 5, 2014

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn's Program

GlobeNewswire June 5, 2014

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

GlobeNewswire June 2, 2014